Sign In
Buy QURE
$46.06
-0.360 (-0.776%)
At Close: Aug 10, 2026
uniQure: Financials And Pipeline Signal A Promising Outlook For Investors
09:19am, Saturday, 20'th May 2023
uniQure's strong financial performance and remarkable revenue growth highlight the company's continued upward trajectory, making it a promising investment opportunity. Innovative gene therapies such a
UniQure (QURE) Reports Q1 Loss, Lags Revenue Estimates
09:56am, Tuesday, 09'th May 2023
UniQure (QURE) came out with a quarterly loss of $1.63 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1 per share a year ago.
UniQure (QURE) Tops Q4 Earnings and Revenue Estimates
09:47am, Monday, 27'th Feb 2023
uniQure (QURE) delivered earnings and revenue surprises of 128.85% and 85.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
uniQure: An FDA Approval, An Advancing Pipeline And A Critical Data Readout
08:46am, Saturday, 18'th Feb 2023
Hemgenix was approved by FDA. uniQure appears undervalued based on the value of milestones and royalties due to the company.
uniQure: Hemgenix Approval Key Catalyst To Move The Needle, Rate Buy
06:35am, Wednesday, 07'th Dec 2022
Recent approval of Hemgenix therapy creates alpha opportunity. Market has responded swiftly and we see upside targets of $31.5 and then $49.
uniQure: FDA Approval Achieved, Along With AMT-130 Moving Forward
03:05pm, Tuesday, 06'th Dec 2022
FDA approval of uniQure N.V.'s Hemgenix for the treatment of adults with Hemophilia B achieved. There is potential to receive European approval of Hemgenix for the treatment of adults with Hemophilia
Why Shares of uniQure Rose 14.61% on Wednesday
05:30pm, Wednesday, 23'rd Nov 2022
A big approval for a gene therapy sent the biotech's stock higher.
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy
02:18pm, Wednesday, 23'rd Nov 2022
uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath
10:24am, Wednesday, 23'rd Nov 2022
The FDA just approved the most expensive drug ever — a hemophilia gene therapy from Carlisle and UniQure — and QURE stock popped Wednesday. The post The FDA Just Approved The Most Expensive Drug E
uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
08:13am, Wednesday, 21'st Sep 2022
uniQure outlicensed AMT-061, EtranaDez, to CSL Behring who will market the gene therapy for hemophilia B. EtranaDez has a PDUFA date in November and if approved, uniQure will collect a $175 m mileston
uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
02:26pm, Tuesday, 30'th Aug 2022
uniQure N.V. has U.S. and European approvals possible of etranacogene dezaparvovec for treatment of Hemophilia B before end of 2022 and early 2023 respectively. uniQure N.V. has already tapped a partn
Why uniQure Stock Is Crashing Today
11:53am, Monday, 08'th Aug 2022
The company is temporarily delaying higher-dose procedures of experimental gene therapy AMT-130.
UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates
09:47am, Monday, 08'th Aug 2022
uniQure (QURE) delivered earnings and revenue surprises of 12.50% and 97.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Up 43% In A Month, Will UniQure Stock See Further Gains?
05:45am, Tuesday, 12'th Jul 2022
This can be attributed to the company reporting positive findings from clinical trials for its Huntington's Disease treatment - AMT-130.
uniQure (QURE) Up on Safety Data From Huntington's Disease Study
11:40am, Friday, 24'th Jun 2022
uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.
